Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Local low-dose IL-2 therapy.

W Den Otter1, L Balemans, J J Battermann

  • 1Department of Cell Biology, Utrecht University, The Netherlands. w.denotter@pobox.accu.uu.nl

Hepato-Gastroenterology
|August 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Informal caregiver well-being during and after patients' treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

International journal of clinical oncology·2017
Same author

Consequences of CT colonography in stenosing colorectal cancer.

International journal of colorectal disease·2016
Same author

BEta versus Gamma Utrecht Trial-Cypher (BEGUT-CYPHER): Is intracoronary brachytherapy still superior to drug-eluting stents?

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2015
Same author

A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same journal

Palliative Surgery for Gastric Cancer with Gastric Outlet Obstruction or Anemia due to Tumor Bleeding.

Hepato-gastroenterology·2016
Same journal

A Novel "Artery First" Approach Allowing Safe Resection in Laparoscopic Pancreaticoduodenectomy: The Uncinate Process First Approach.

Hepato-gastroenterology·2016
Same journal

A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.

Hepato-gastroenterology·2016
Same journal

A Novel Approach for Endoscopic Papillary Balloon Dilation with the Guidewire Left in the Pancreatic Duct to Ensure Pancreatic Stenting.

Hepato-gastroenterology·2016
Same journal

Which Factors are Predictive for Mortality among Hospitalized Patients with Cirrhosis?

Hepato-gastroenterology·2016
Same journal

Hydrodynamics Analysis and CFD Simulation of Portal Venous System by TIPS and LS.

Hepato-gastroenterology·2016
See all related articles

Local application of Interleukin-2 (IL-2) activates tumor-infiltrating cells for effective cancer treatment. This targeted approach offers a virtually non-toxic, potent therapy, potentially curing cancer with single injections and enhancing other treatments.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Interleukin-2 (IL-2) is recognized for its potent anti-cancer properties.
  • Effective IL-2 therapy necessitates precise administration, particularly at the tumor site.
  • Tumor-infiltrating lymphocytes at the normal-malignant tissue interface are key targets for IL-2 activation.

Purpose of the Study:

  • To investigate the efficacy and safety of locally applied Interleukin-2 (IL-2) in cancer treatment.
  • To highlight the advantages of targeted IL-2 delivery to the tumor microenvironment.
  • To explore the potential of IL-2 in combination therapies and as a standalone treatment.

Main Methods:

  • Local administration of Interleukin-2 (IL-2) directly to the tumor site.
  • Activation of tumor-infiltrating lymphocytes via targeted IL-2 delivery.

Related Experiment Videos

  • Evaluation of IL-2's therapeutic effects in conjunction with irradiation and Cisplatin.

    • Main Results:

    • Local IL-2 application allows for significantly lower, yet effective, doses.
    • Even a single injection of locally applied IL-2 has demonstrated cancer-curing potential.
    • IL-2 enhances the therapeutic efficacy of conventional treatments like irradiation and Cisplatin.
    • Locally administered IL-2 therapy exhibits a virtually non-toxic profile.

    Conclusions:

    • Targeted, local application of Interleukin-2 (IL-2) is a highly effective strategy for cancer treatment.
    • IL-2's ability to activate tumor-infiltrating cells locally offers a potent and safe therapeutic option.
    • Local IL-2 therapy presents a promising approach, either alone or as an adjuvant to other cancer treatments, with minimal toxicity.